Results
Infacort® and hydrocortisone tablets were administered to subjects at 07:00 (fasted) with 200mL water. Blood samples were taken at hourly intervals for 12 hours and serum cortisol concentration was determined by tandem mass spectrometry LC-MS-MS (Applied Biosystems, US). Pharmacokinetic end-points were derived from the individual serum cortisol concentration-time data using WinNonlin Phoenix 32.
Infacort® and hydrocortisone tablets at a dose of 10 mg are bioequivalent as reflected by the geometric LSmean 90 % CI for ratios of Cmax, AUC 0-t and AUC 0-inf within 0.8 -1.25. The majority of subjects described Infacort® as, "not good or bad", for smell (81.3% to 87.5 % of subjects), feel in the mouth (68.8 % of subjects) and taste (68.8 % to 81.3 % of subjects) using a palatability questionnaire Hydrocortisone 10mg
Conclusions and Discussion
Infacort® was safe, well tolerated and of neutral taste when administered as a single oral dose of 10 mg. Infacort® 10mg was bioequivalent to 10mg hydrocortisone tablets with respect to C max and AUC . Infacort® demonstrated dose-linearity between 0.5 mg and 10mg.
Infacort® has the potential to be the first, regulatory approved, specially developed paediatric formulation for the treatment of children suffering from adrenal insufficiency under 6 years of age in Europe. The study was performed under a Paediatric Investigation Plan approved by the European Medicines Agency (EMEA-001283-PIP01-12) and further studies in the target patient group are planned. 
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